Market Intelligence, Clinical Progress, and High-Purity Reagents for Smooth Muscle & Cytoskeletal Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LMOD1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LMOD1 Recombinant Full-Length & Truncation Mutants (including WH2 domain and Tropomyosin-binding domain constructs). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed by Mass Spec. | View LMOD1 Products |
| Gene Delivery | LMOD1 Lentivirus Particles (ORF/pLenti). Full-length ORF for stable smooth muscle cell line construction. HEK293 Expressed. | View LMOD1 Products |
| Benchmark Ab | Anti-LMOD1 Recombinant Monoclonal Antibody (Sequence Verified) for Western, IHC, IF; Polyclonal Antibody also available for validation. | View LMOD1 Products |
| Validator | LMOD1 siRNA Set (3 target-specific + 1 scramble). For knockdown verification and specificity controls. | View LMOD1 Products |
| Related Target: LMOD2 | Cardiac muscle paralog for subfamily selectivity profiling and counter-screening. | View LMOD2 Products |
| Related Target: LMOD3 | Skeletal muscle paralog for off-target liability assessment. | View LMOD3 Products |
| Related Target: ACTA2 | Primary binding partner (α-smooth muscle actin) for LMOD1-actin interaction assays. | View ACTA2 Products |
| Related Target: TMOD1 | Tropomodulin-1, antagonistic capping protein for complementary pathway analysis. | View TMOD1 Products |
| Related Target: MYH11 | Smooth muscle myosin heavy chain biomarker for contractility studies. | View MYH11 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Actin-binding & Polymerization Kinetics (Pyrene-Actin) | High-purity LMOD1 (>95%) with validated actin-binding capability, verified N-terminal WH2 domains. Theoretical MW confirmed by Mass Spec & SDS-PAGE. |
| Subfamily Selectivity (LMOD1 vs LMOD2/LMOD3) | Ortholog panel: Human LMOD1, LMOD2, LMOD3 proteins strictly Sequence Verified for selectivity assays. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno LMOD1 ortholog proteins available with sequence-verified conservation. |
| Domain Mapping (WH2 vs TMB) | Truncation mutants strictly verified by mass spec for precise domain studies. |
| Stable Expression in Contractile Cell Models | Lentivirus Premade Particles for stable LMOD1 overexpression in smooth muscle cell lines. |
| Loss-of-function Specificity / False Positives | Validated siRNA included for knockdown specificity checks in cellular context. |
| Autoantibody Screening / Diagnostics | Sequence Verified, High Purity (>95%) Human LMOD1 proteins for ELISA; Recombinant positive control antibodies included. |
| Intracellular Target Accessibility | Lentivirus and siRNA tools enable functional intracellular assays (overexpression/knockdown). |
Live LMOD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly via these curated search links:
- ➤ View Active Clinical Trials
- ➤ Latest Research (smooth muscle, drug resistance, diagnostics)
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
Research on LMOD1 (Leiomodin-1) is heavily concentrated in smooth muscle biology, driven by its essential role in contractile apparatus assembly. Genetic linkage to visceral myopathies (e.g., megacystis-microcolon-intestinal hypoperistalsis syndrome, MMIHS) and vascular dysfunction positions it as a novel target for gastrointestinal motility disorders and vascular smooth muscle disorders. LMOD1 also serves as an autoantigen in rare conditions, prompting diagnostic development. The clinical landscape is shifting from structural biology to therapeutic modulation: early biotech programs are exploring gene therapy, small molecule modulators, and peptide inhibitors aimed at disrupting the LMOD1-actin interface to modulate smooth muscle tone without affecting striated muscle. Demand for high-quality biochemical and cellular reagents (recombinant proteins, antibodies, lentivirus, siRNA) is accelerating as the field advances from target validation to lead optimization.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Academic & Early Biotech | Vascular Smooth Muscle Disorders, Vascular Spasm | PPI Assay / Actin Polymerization Inhibition (Need high-purity LMOD1 + actin binding domains; WT vs mutant proteins) |
| Gene Therapy / mRNA | Rare Disease Focus | MMIHS, Intestinal Pseudo-obstruction, Smooth Muscle Myopathies | Stable Cell Lines / Expression Validation (Need ORF Lentivirus & Benchmark Abs) |
| Biologic / Peptide | Emerging / Academic Consortia | Asthma, Hypertension, Gastroparesis | SPR/BLI Binding Assay (Need high-purity LMOD1 domains & selectivity panel) |
| Diagnostics | Academic & Specialty Labs | MMIHS, Autoimmune Disorders | ELISA Assays (Need high-purity, sequence-verified human LMOD1 proteins) |